Aehr Test Systems filings document material events, operating results, capital actions and governance matters for a semiconductor test and burn-in equipment company. Recent Form 8-K disclosures include quarterly financial-result releases covering revenue, bookings, backlog, cash position and GAAP and non-GAAP earnings measures.
The filing record also includes capital-structure disclosures tied to an at-the-market common stock offering under a Form S-3 registration statement, along with proxy and annual meeting materials. Those governance filings address director elections, shareholder voting results, amendments to the company’s equity incentive and employee stock purchase plans, auditor ratification and executive-compensation matters.
A shareholder of AEHR has filed a Rule 144 notice to sell 3,000 shares of common stock, with an aggregate market value of $82,715.25. The planned sale is through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 02/09/2026.
The filing notes that 30,627,342 shares of common stock were outstanding. The 3,000 shares to be sold were acquired through multiple restricted stock vesting compensation events between 10/02/2025 and 01/27/2026, with each vesting treated as compensation from the issuer.
Baillie Gifford & Co has reported a passive stake in AEHR Test Systems’ common stock below the 5% threshold. The firm beneficially owns 1,290,734 shares, representing 4.3% of the class, with sole voting and dispositive power over all of these shares.
Baillie Gifford & Co, an investment adviser based in Scotland, states that the AEHR shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the company or participating in any control-related transactions.
Aehr Test Systems director Howard T. Slayen reported gifting 15,000 shares of common stock to family trusts. On 02/04/2026, he made three separate transfers of 5,000 shares each at a reported price of $0 per share, reflecting non-cash gifts.
The gifts went to the Leila James Slayen Trust, the Allison Elizabeth Slayen Trust, and the Max William Slayen Trust. After these transactions, Slayen beneficially owned 203,328 shares of Aehr Test Systems common stock, which the filing states includes shares subject to unvested restricted stock units.
AEHR Test Systems executive Alberto Salamone reported a small insider transaction related to equity compensation. On February 1, 2026, 234 shares of common stock were withheld at $25.64 per share to cover tax obligations when his restricted stock units vested. The filing explains this was not an open-market sale, but a share withholding for taxes. After this transaction, he beneficially owns 76,906 shares of AEHR common stock, which includes shares subject to unvested restricted stock units.
A holder of AEHR common stock has filed a notice of intended share sales under SEC Rule 144. The filing covers a planned sale of 503 common shares through The Charles Schwab Corporation on NASDAQ, with an aggregate market value of $13,440.16 as of the filing details.
The securities were originally acquired on 10/19/2022 as equity compensation from the issuer. The filing also notes that Laura A. Oliphant sold 4,546 common shares on 01/22/2026 for gross proceeds of $142,750.68, reflecting recent selling activity related to the same issuer.
Aehr Test Systems vice president Alistair N. Sporck reported a routine tax-related share withholding tied to equity compensation. On January 27, 2026, 152 shares of common stock were withheld at $27.75 per share to satisfy tax obligations upon vesting of restricted stock units, which is not an open market sale.
After this transaction, Sporck beneficially owned 28,153 shares of Aehr Test Systems common stock directly, including shares subject to unvested restricted stock units, and 5,214 shares indirectly through a trust.
Aehr Test Systems executive Vernon Rogers reported a small tax-related share withholding. On January 27, 2026, 160 shares of common stock were withheld at $27.75 per share to cover tax obligations triggered by the vesting of restricted stock units.
This transaction is coded "F," indicating a tax withholding rather than an open-market sale, and the disclosure states it does not represent a sale by the reporting person. After this event, Rogers beneficially owned 177,206 shares of Aehr Test Systems common stock, which includes shares underlying unvested restricted stock units.
AEHR Test Systems CTO Donald P. Richmond II reported an automatic share withholding related to equity compensation. On 01/27/2026, 117 shares of common stock were withheld at $27.75 per share to cover tax obligations on vesting restricted stock units, which is not a market sale. Following this, he beneficially owned 213,217 shares directly, including shares subject to unvested restricted stock units.
Aehr Test Systems President and CEO Erickson Gayn, also a director, reported an automatic share withholding related to equity compensation. On January 27, 2026, 820 shares of common stock were withheld at $27.75 per share to cover tax obligations on vested restricted stock units, which is not a market sale.
After this transaction, Gayn beneficially owned 251,299 shares of common stock directly. He also reported an additional 291,628 shares held indirectly through a trust, which includes shares subject to unvested restricted stock units and unvested restricted shares.
AEHR TEST SYSTEMS Chief Operating Officer ENGINEER ADIL reported an automatic share withholding related to equity compensation. On 01/27/2026, 163 shares of common stock were withheld at $27.75 per share to cover tax obligations upon vesting of restricted stock units, which the company notes does not represent a sale. After this transaction, ADIL beneficially owned 45,676 common shares, including shares subject to unvested restricted stock units, all held in direct ownership.